Executive Briefing

1. Headline

17 cross-response inconsistency flags across 70 AI answers to 10 questions establish a meaningful baseline risk, concentrated in safety and prescribing-information content. The dominant issue is not competitor visibility—no competitor brands were mentioned—but whether contraindications, pregnancy considerations, and other safety qualifiers appear consistently.

2. This week at a glance

Additional safety/regulatory themes: pregnancy/lactation 18, off-label use 17, allergic reactions 14.

Model-level attribution is not relied upon here; findings are reported across answer instances because reliable model attribution is not established in the supplied data.

3. Trajectory (multi-week)

This is a baseline week with no trend comparison yet. The available history contains only the week ending August 22, 2026, so no improvement, degradation, or inflection can be established. Competitor visibility is also currently absent, but one week is insufficient to determine whether that is stable.

4. Where the risk actually is

• Contraindication coverage varies for scabies dosing (query 266): 5 of 7 answers mentioned contraindication-related content, while 2 omitted it. Six of 7 omitted the infection-risk theme. A user may receive the same dosing guidance with materially different safety context.
• Contraindications answer (query 268): pregnancy/lactation was included in 6 of 7 responses and omitted in 1. For a question explicitly asking when ivermectin should be avoided, that omission creates a direct patient-safety and medical-information consistency concern.
• Serious adverse reactions (query 269): contraindication-related content appeared in only 3 of 7 responses, while pregnancy/lactation appeared in 2 of 7. Users asking when to stop treatment or seek care may receive incomplete risk framing.

5. Recommended actions

1. Medical Affairs + Regulatory: Create a canonical, indication- and formulation-specific safety brief covering contraindications, pregnancy/lactation, pediatric weight limits, interactions, and serious adverse reactions. This directly addresses the 17 inconsistency flags.
2. Medical Information/content team: Publish or strengthen authoritative pages for scabies dosing, strongyloidiasis in older adults, and adverse-event escalation, with explicit qualifiers and local-label language. Prioritize queries 266, 267, 268, and 269.
3. Content/SEO: Correct product distinctions—especially human versus veterinary formulations and oral versus topical use—and reinforce that products are not interchangeable. This reduces ambiguity in the brand questions.
4. PV + Medical Affairs: Review the inconsistent adverse-event and infection-risk language for escalation or monitoring implications; use the current baseline to define a target for improved consistency next week.
5. Analytics owner: Establish the next-week comparison and validate model attribution fields so future reporting can separate response-variant variability from true model-level differences.